Abstract：
UNASSIGNED: Mogamulizumab is an anti-C-C chemokine receptor 4 antibody that is increasingly being used to treat T-cell malignancies such as cutaneous T-cell lymphoma, adult T-cell leukemia-lymphoma, and peripheral T-cell lymphoma. Because CCR4 is expressed on both malignant T-cells and regulatory T-cells (Tregs), mogamulizumab can be associated with increased immune-related adverse events (irAEs). While there is abundant literature on mogamulizumab-associated rash (MAR) and graft-versus-host disease (GVHD), other reported irAEs have not been collated into a single review.
UNASSIGNED: This narrative review covers irAEs associated with mogamulizumab in patients with T-cell lymphomas, focusing on events other than MAR and GVHD. We searched PubMed and Google Scholar for case reports, case series, chart reviews, and clinical trials published from inception to March 2024. Identified events include alopecia, vitiligo, arthritis, psoriasis, myocarditis, myositis/polymyositis, hepatitis, and others.
UNASSIGNED: Mogamulizumab\'s ability to augment the host immune response through Treg depletion adds to its efficacy but has wide-ranging implications for autoimmunity across multiple organ systems, similar to immune checkpoint inhibitor therapy. Occurrence of irAEs may be associated with improved overall clinical response, although long-term follow-up studies are needed.
UNASSIGNED: This narrative review covers irAEs associated with mogamulizumab in patients with T-cell lymphomas, focusing on events other than MAR and GVHD. We searched PubMed and Google Scholar for case reports, case series, chart reviews, and clinical trials published from inception to March 2024. Identified events include alopecia, vitiligo, arthritis, psoriasis, myocarditis, myositis/polymyositis, hepatitis, and others.
UNASSIGNED: Mogamulizumab\'s ability to augment the host immune response through Treg depletion adds to its efficacy but has wide-ranging implications for autoimmunity across multiple organ systems, similar to immune checkpoint inhibitor therapy. Occurrence of irAEs may be associated with improved overall clinical response, although long-term follow-up studies are needed.
摘要：
■Mogamulizumab是一种抗C-C趋化因子受体4抗体，越来越多地用于治疗T细胞恶性肿瘤，例如皮肤T细胞淋巴瘤，成人T细胞白血病淋巴瘤,和外周T细胞淋巴瘤。因为CCR4在恶性T细胞和调节性T细胞（Tregs）上都表达，mogamulizumab可能与免疫相关不良事件(irAEs)增加相关.虽然有大量关于莫加穆利珠单抗相关皮疹（MAR）和移植物抗宿主病（GVHD）的文献，其他报告的irAE尚未整理成单一的审查。
■本叙述性综述涵盖了T细胞淋巴瘤患者与mogamulizumab相关的irAE，专注于MAR和GVHD以外的事件。我们搜索了PubMed和谷歌学者的病例报告，案例系列,图表评论，和临床试验从开始到2024年3月发表。确定的事件包括脱发，白癜风,关节炎,牛皮癣,心肌炎,肌炎/多发性肌炎，肝炎，和其他人。
Mogamulizumab通过Treg耗竭增强宿主免疫反应的能力增加了其功效，但对多个器官系统的自身免疫具有广泛的影响，类似于免疫检查点抑制剂治疗。irAE的发生可能与改善的总体临床反应有关，尽管需要长期随访研究.
■本叙述性综述涵盖了T细胞淋巴瘤患者与mogamulizumab相关的irAE，专注于MAR和GVHD以外的事件。我们搜索了PubMed和谷歌学者的病例报告，案例系列,图表评论，和临床试验从开始到2024年3月发表。确定的事件包括脱发，白癜风,关节炎,牛皮癣,心肌炎,肌炎/多发性肌炎，肝炎，和其他人。
Mogamulizumab通过Treg耗竭增强宿主免疫反应的能力增加了其功效，但对多个器官系统的自身免疫具有广泛的影响，类似于免疫检查点抑制剂治疗。irAE的发生可能与改善的总体临床反应有关，尽管需要长期随访研究.
